Literature DB >> 9420229

Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2.

E A Rutledge1, C L Halbert, D W Russell.   

Abstract

Adeno-associated viruses (AAVs) are single-stranded dependent parvoviruses being developed as transducing vectors. Although at least five serotypes exist (AAV types 1 to 5 [AAV1 to -5]), only AAV2, AAV3, and AAV4 have been sequenced, and the vectors in use were almost all derived from AAV2. Here we report the cloning and sequencing of a second AAV3 genome and a new AAV serotype designated AAV6 that is related to AAV1. AAV2, AAV3, and AAV6 were 82% identical at the nucleotide sequence level, and AAV4 was 75 to 78% identical to these AAVs. Significant sequence variation was noted in portions of the capsid proteins that presumably are responsible for serotype-specific functions. Vectors produced from AAV3 and AAV6 differed from AAV2 vectors in host range and serologic reactivity. The AAV3 and AAV6 vector serotypes were able to transduce cells in the presence of serum from animals previously exposed to AAV2 vectors. Our results suggest that vectors based on alternative AAV serotypes will have advantages over existing AAV2 vectors, including the transduction of different cell types, and resistance to neutralizing antibodies against AAV2. This could be especially important for gene therapy, as significant immunity against AAV2 exists in human populations and many protocols will likely require multiple vector doses.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9420229      PMCID: PMC109378     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

1.  Adeno-associated virus vector integration junctions.

Authors:  E A Rutledge; D W Russell
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector.

Authors:  X Xiao; J Li; R J Samulski
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

3.  A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication.

Authors:  R J Samulski; L S Chang; T Shenk
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

4.  Characterization of a newly derived human sarcoma cell line (HT-1080).

Authors:  S Rasheed; W A Nelson-Rees; E M Toth; P Arnstein; M B Gardner
Journal:  Cancer       Date:  1974-04       Impact factor: 6.860

5.  Epidemiology of adenovirus-associated virus infection in a nursery population.

Authors:  N R Blacklow; M D Hoggan; A Z Kapikian; J B Austin; W P Rowe
Journal:  Am J Epidemiol       Date:  1968-11       Impact factor: 4.897

6.  A minute circular DNA from Escherichia coli 15.

Authors:  N R Cozzarelli; R B Kelly; A Kornberg
Journal:  Proc Natl Acad Sci U S A       Date:  1968-07       Impact factor: 11.205

7.  Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3.

Authors:  S Muramatsu; H Mizukami; N S Young; K E Brown
Journal:  Virology       Date:  1996-07-01       Impact factor: 3.616

8.  A maltose-binding protein/adeno-associated virus Rep68 fusion protein has DNA-RNA helicase and ATPase activities.

Authors:  R S Wonderling; S R Kyöstiö; R A Owens
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

9.  Cloning of infectious adeno-associated virus genomes in bacterial plasmids.

Authors:  C A Laughlin; J D Tratschin; H Coon; B J Carter
Journal:  Gene       Date:  1983-07       Impact factor: 3.688

10.  Conserved arrangement of nested genes at the Drosophila Gart locus.

Authors:  S Henikoff; M K Eghtedarzadeh
Journal:  Genetics       Date:  1987-12       Impact factor: 4.562

View more
  165 in total

Review 1.  Adeno-associated virus vectors and hematology.

Authors:  D W Russell; M A Kay
Journal:  Blood       Date:  1999-08-01       Impact factor: 22.113

2.  Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure.

Authors:  M Moskalenko; L Chen; M van Roey; B A Donahue; R O Snyder; J G McArthur; S D Patel
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

3.  Adeno-associated viruses undergo substantial evolution in primates during natural infections.

Authors:  Guangping Gao; Mauricio R Alvira; Suryanarayan Somanathan; You Lu; Luk H Vandenberghe; John J Rux; Roberto Calcedo; Julio Sanmiguel; Zahra Abbas; James M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-25       Impact factor: 11.205

4.  Characterization of the transcription profile of adeno-associated virus type 5 reveals a number of unique features compared to previously characterized adeno-associated viruses.

Authors:  Jianming Qiu; Ramnath Nayak; Gregory E Tullis; David J Pintel
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

5.  Identification of the heparin binding site on adeno-associated virus serotype 3B (AAV-3B).

Authors:  Thomas F Lerch; Michael S Chapman
Journal:  Virology       Date:  2011-12-09       Impact factor: 3.616

6.  Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain.

Authors:  Mihail Y Mastakov; Kristin Baer; C Wymond Symes; Claudia B Leichtlein; Robert M Kotin; Matthew J During
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

7.  The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy.

Authors:  Qing Xie; Weishu Bu; Smita Bhatia; Joan Hare; Thayumanasamy Somasundaram; Arezki Azzi; Michael S Chapman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-22       Impact factor: 11.205

8.  Cloning of an avian adeno-associated virus (AAAV) and generation of recombinant AAAV particles.

Authors:  Ioannis Bossis; John A Chiorini
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

9.  Bronchoalveolar fluid is not a major hindrance to virus-mediated gene therapy in cystic fibrosis.

Authors:  C P Rooney; G M Denning; B P Davis; D M Flaherty; J A Chiorini; J Zabner
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice.

Authors:  Jianping Lin; Yan Zhi; Lauren Mays; James M Wilson
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.